Shattuck Labs, Inc. Logo

Shattuck Labs, Inc.

STTK

(1.2)
Stock Price

3,68 USD

-71.46% ROA

-62.4% ROE

-4.53x PER

Market Cap.

468.537.804,00 USD

3.89% DER

0% Yield

-5211.89% NPM

Shattuck Labs, Inc. Stock Analysis

Shattuck Labs, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Shattuck Labs, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.68x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (3%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

Negative ROE (-53.43%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-57.78%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Shattuck Labs, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Shattuck Labs, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Shattuck Labs, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Shattuck Labs, Inc. Revenue
Year Revenue Growth
2018 22.442.000
2019 9.887.000 -126.98%
2020 9.934.000 0.47%
2021 30.017.000 66.91%
2022 652.000 -4503.83%
2023 2.744.000 76.24%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Shattuck Labs, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 24.807.000
2019 29.218.000 15.1%
2020 37.483.000 22.05%
2021 56.563.000 33.73%
2022 82.899.000 31.77%
2023 96.844.000 14.4%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Shattuck Labs, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 3.783.000
2019 5.736.000 34.05%
2020 9.382.000 38.86%
2021 18.723.000 49.89%
2022 21.082.000 11.19%
2023 20.292.000 -3.89%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Shattuck Labs, Inc. EBITDA
Year EBITDA Growth
2018 -5.284.000
2019 -23.445.000 77.46%
2020 -36.931.000 36.52%
2021 -43.889.000 15.85%
2022 -103.329.000 57.52%
2023 -110.312.000 6.33%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Shattuck Labs, Inc. Gross Profit
Year Gross Profit Growth
2018 22.442.000
2019 9.887.000 -126.98%
2020 9.934.000 0.47%
2021 30.017.000 66.91%
2022 652.000 -4503.83%
2023 2.744.000 76.24%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Shattuck Labs, Inc. Net Profit
Year Net Profit Growth
2018 -7.388.000
2019 -23.883.000 69.07%
2020 -35.436.000 32.6%
2021 -44.349.000 20.1%
2022 -100.561.000 55.9%
2023 -110.164.000 8.72%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Shattuck Labs, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 0
2019 -1 100%
2020 -2 50%
2021 -1 -100%
2022 -2 50%
2023 -3 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Shattuck Labs, Inc. Free Cashflow
Year Free Cashflow Growth
2018 -8.081.000
2019 -21.445.000 62.32%
2020 -34.386.000 37.63%
2021 -65.042.000 47.13%
2022 -106.112.000 38.7%
2023 -16.751.000 -533.47%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Shattuck Labs, Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -6.903.000
2019 -20.975.000 67.09%
2020 -33.659.000 37.68%
2021 -57.116.000 41.07%
2022 -94.498.000 39.56%
2023 -16.732.000 -464.77%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Shattuck Labs, Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 1.178.000
2019 470.000 -150.64%
2020 727.000 35.35%
2021 7.926.000 90.83%
2022 11.614.000 31.75%
2023 19.000 -61026.32%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Shattuck Labs, Inc. Equity
Year Equity Growth
2018 -11.081.000
2019 -34.548.000 67.93%
2020 309.861.000 111.15%
2021 271.786.000 -14.01%
2022 176.157.000 -54.29%
2023 112.783.000 -56.19%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Shattuck Labs, Inc. Assets
Year Assets Growth
2018 68.161.000
2019 44.969.000 -51.57%
2020 348.988.000 87.11%
2021 298.585.000 -16.88%
2022 205.324.000 -45.42%
2023 130.457.000 -57.39%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Shattuck Labs, Inc. Liabilities
Year Liabilities Growth
2018 79.242.000
2019 79.517.000 0.35%
2020 39.127.000 -103.23%
2021 26.799.000 -46%
2022 29.167.000 8.12%
2023 17.674.000 -65.03%

Shattuck Labs, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.03
Net Income per Share
-2.19
Price to Earning Ratio
-4.53x
Price To Sales Ratio
351.49x
POCF Ratio
-4.93
PFCF Ratio
-5.4
Price to Book Ratio
3.74
EV to Sales
324.3
EV Over EBITDA
-4.49
EV to Operating CashFlow
-5.05
EV to FreeCashFlow
-4.98
Earnings Yield
-0.22
FreeCashFlow Yield
-0.19
Market Cap
0,47 Bil.
Enterprise Value
0,43 Bil.
Graham Number
11.45
Graham NetNet
1.96

Income Statement Metrics

Net Income per Share
-2.19
Income Quality
0.9
ROE
-0.64
Return On Assets
-0.54
Return On Capital Employed
-0.62
Net Income per EBT
0.99
EBT Per Ebit
0.95
Ebit per Revenue
-55.5
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
14.74
Research & Developement to Revenue
60.74
Stock Based Compensation to Revenue
5.25
Gross Profit Margin
-1.54
Operating Profit Margin
-55.5
Pretax Profit Margin
-52.68
Net Profit Margin
-52.12

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-2.02
Free CashFlow per Share
-2.04
Capex to Operating CashFlow
0.01
Capex to Revenue
-0.81
Capex to Depreciation
-0.27
Return on Invested Capital
-0.8
Return on Tangible Assets
-0.71
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0.03

Balance Sheet

Cash per Share
2,38
Book Value per Share
2,66
Tangible Book Value per Share
2.66
Shareholders Equity per Share
2.66
Interest Debt per Share
0.06
Debt to Equity
0.04
Debt to Assets
0.03
Net Debt to EBITDA
0.38
Current Ratio
8.04
Tangible Asset Value
0,11 Bil.
Net Current Asset Value
0,10 Bil.
Invested Capital
0.04
Working Capital
0,10 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Shattuck Labs, Inc. Dividends
Year Dividends Growth

Shattuck Labs, Inc. Profile

About Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

CEO
Dr. Taylor H. Schreiber M.D.,
Employee
75
Address
500 West 5th Street
Austin, 78703

Shattuck Labs, Inc. Executives & BODs

Shattuck Labs, Inc. Executives & BODs
# Name Age
1 Dr. Thomas Lampkin Pharm.D.
Senior Vice President of Regulatory Affairs
70
2 Dr. Stephen Stout J.D., Ph.D.
General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer
70
3 Mr. Conor Richardson CPA
Vice President of Investor Relations
70
4 Ms. Casi DeYoung
Chief Business Officer
70
5 Mr. Suresh de Silva Ph.D.
Chief Scientific Officer of GADLEN Platform
70
6 Mr. George Fromm Ph.D.
Chief Scientific Officer of ARC Platform
70
7 Mr. Andrew R. Neill M.B.A.
Chief Financial Officer
70
8 Dr. Taylor H. Schreiber M.D., Ph.D.
Co-Founder, Chief Executive Officer & Director
70
9 Dr. Abhinav A. Shukla Ph.D.
Chief Technical Officer
70
10 Dr. Arundathy Nirmalini Pandite M.B.A., M.D.
Chief Medical Officer
70

Shattuck Labs, Inc. Competitors